FDA Inspection 1279894 — Kite Pharma, Inc.

Kite Pharma, Inc. — FEI 3012583739

The FDA completed an inspection of Kite Pharma, Inc. on August 27, 2025 in El Segundo, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 27, 2025
Fiscal Year
2025
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
El Segundo, CA (United States)

Citations

IDCFRDescription
127021 CFR 211.68(b)input/output verification
136121 CFR 211.100(a)Absence of Written Procedures
356121 CFR 211.56(b)Written sanitation procedures lacking
440221 CFR 211.192Written record of investigation incomplete